Rostaporfin Miravant Medical Technologies

IDrugs

Volumn 5, Issue 2, 2002, Pages 180-186

  Hunt, David W C ^a  

^a QLT Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PHOTOSENSITIZING AGENT; PLACEBO; PNU 167524; PURLYTIN; ROSTAPORFIN; TIN ETHYL ETIOPURPURIN DICHLORIDE; TIN OCTAETHYLBENZOCHLORIN; TIN OCTAETHYLPURPURIN; UNCLASSIFIED DRUG; ZINC ETHYL ETIOPURPURIN DICHLORIDE; ZINC OCTAETHYLPURPURIN;

BLOOD RETINA BARRIER; BREAST CANCER; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOXICITY; HUMAN; HYDROPHOBICITY; LIGHT ABSORPTION; LIGHT EXPOSURE; METASTASIS; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STRUCTURE ACTIVITY RELATION; SUBRETINAL NEOVASCULARIZATION;

EID: 0141784091     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. 85236 New photosensitizers for the photodynamic therapy of tumors. Morgan AR, Selman SH Drugs Future 1988 13 12 1073-1082
2. 180314 Pharmacia signs license agreement for PDT's photodynamic drug. Pharmacia Press Release 1995 July 07
3. 206998 Photodynamic therapy (PDT) of experimental choroidal neovascularization with tin ethyl etiopurpurin. Baumal CR, Puliafito CA, Pieroth L, Schuman JS, Lahav M, Pedut Kloizmant, Kiernan C, Coker JG, Wilkins JR, Fujimoto JG, Crean DH Invest Ophthalmol Vis Sci 1996 37 3 S122
4. 206999 Photodynamic therapy response of choriocapillaris using tin ethyl etiopurpurin (SnET2). Crean DH, Peyman GA, Moshfeghi DM, Moshfeghi A, Khoobehi B, Doiron DR Invest Ophthalmol Vis Sci 1996 37 3 S122
5. 207006 Comparative pharmacokinetics of the photosensitizer tin-etiopurpurin in dogs and rats. Frazier DL, Barnhill MA, Vodinh T, Legendre AM, Overholt BF J Vet Pharmacol Ther 1992 15 3 275-281 This study describes the pharmacokinetic attributes of rostaporfin in Sprague Dawley rats and Beagle dogs.
6. 207008 The distribution of the tumor photosensitizers Zn(II)- phthalocyanine and Sn(IV)-etiopurpurin among rabbit plasma proteins. Polo L, Reddi E, Garbo GM, Morgan AR, Jori G Cancer Lett 1992 66 3 217-223
7. 207009 Binding of drugs to human plasma proteins, exemplified by Sn(IV)-etiopurpurin dichloride delivered in cremophor and DMSO. Kongshaug M, Moan J, Cheng LS, Garbo GM, Kolboe S, Morgan AR, Rimington C Int J Biochem 1993; 25 5 739-760
8. 207011 Photodynamic therapy: Effect on the endothelial cell of the rat aorta. He DP, Hampton JA, Keck R, Selman SH Photochem Photobiol 1991 54 5 801-804
9. 207012 Sites and efficacy of photodamage by tin etiopurpurin in vitro using different delivery systems. Kessel D, Morgan A, Garbo GM Photochem Photobiol 1991 54 2 193-196
10. 207014 Hemodynamic effect of the metallopurpurin SnET2 and light on transplantable FANFT induced bladder tumor. Selman SH, Qin BS, James HR, Keck RW, Garbo GM, Morgan AR J Urol 1990 143 3 630-633
11. 207015 Metallopurpurins and light: Effect on transplantable rat bladder tumors and murine skin. Morgan AR, Garbo GM, Keck RW, Eriksen LD, Selman SH Photochem Photobiol 1990 51 5 589-592
12. 207017 New photosensitizers for photodynamic therapy: Combined effect of metallopurpurin derivatives and light on transplantable bladder tumors. Morgan AR, Garbo GM, Keck RW, Selman SH Cancer Res 1988 48 1 194-198 This was the first article to detail the synthesis and photodynamic activity of rostaporfin.
13. 207407 PDT Inc begins clinical trials in ophthalmology. PDT Inc Press Release 1996 May 08
14. 207423 Binding of etiopurpurin and tin-coordinated etiopurpurin to human plasma proteins. Delivery in cremophore EL and dimethyl sulfoxide. Kongshaug M, Cheng LS, Moan J, Morgan AR Int J Biochem Cell Biol 1995 27 1 71-87
15. 233520 Rapid initiation of apoptosis by photodynamic therapy. Luo Y, Chang CK, Kessel D Photochem Photobiol 1996 63 4 528-534 A substantial and detailed primary reference discussing the chemical attributes of different porphyrin photosensitizers and the potent pro-apoptotic activity of rostaporfin against tumor cells in vitro.
16. 233523 Transperineal photodynamic ablation of the canine prostate. Selman SH, Keck RW, Hampton JA J Urol 1996 156 1 258-260
17. 233524 Pyrrolic photosensitizers. Sternberg E, Dolphin D Curr Med Chem 1996 3 4 239-272 A detailed discussion of the chemical attributes of different porphyrin photosensitizers.
18. 233525 Purpurins and benzochlorins as sensitizers for photodynamic therapy. Garbo GM J Photochem Photobiol B Biol 1996 34 2-3 109-116
19. 233533 Ocular toxicity of SnET-2. Ribeiro I, Peyman GA, Khoobehi B, Moshfeghi A Invest Ophthalmol Vis Sci 1994 35 4 2221
20. 233537 New drugs and future developments in photodynamic therapy. Ash DV, Brown SB Eur J Cancer 1993 29A 12 1781-1783
21. 233538 Second generation photodynamic agents: A review. Sternberg ED, Dolphin D J Clin Laser Med Surg 1993 11 5 233-241
22. 267521 Miravant and Medicis announce collaboration in dermatology. Miravant Medical Technologies Press Release 1997 October 28
23. 278825 Phase I/II trial shows PhotoPoint improves vision in patients with an advanced stage of macular degeneration; Results encouraging for short-term treatment of debilitating eye condition. Miravant Medical Technologies Press Release 1998 February 20
24. 289078 Miravant, Pharmacia & Upjohn execute new purlytin agreements. Miravant Medical Technologies Press Release 1998 June 09
25. 297967 Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: Case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). Kaplan MJ, Somers RG, Greenberg RH, Ackler J J Surg Oncol 1998 67 2 121-125
26. 303978 Photodynamic therapy. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q J Natl Cancer Inst 1998 90 12 889-905 This article, prepared by a number of opinion leaders in the field, is considered to be the classic review of PDT. It covers basic mechanisms of action at the cellular and tissue levels as well as the various clinical applications for this technology including AMD. The state of knowledge related to the action of photosensitizers at the subcellular level, the relationship of PDT to antitumor immunity, as well as the clinical application of PDT are summarized.
27. 310845 Miravant enrolling patients in phase III clinical trials in macular degeneration. Miravant Medical Technologies Press Release 1999 January 06
28. 311992 Pharmacia & Upjohn increases development funding for Miravant's SnET2 in age-related macular degeneration Pharmacia & Upjohn Inc Press Release 1999 January 19
29. 313095 Pharmaceutical & Biotechnology Bulletin. Merrill Lynch Capital Markets 1999 January 21
30. 343758 A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Mang TS, Allison R, Hewson G, Snider W, Moskowitz R Cancer J From Scientific Am 1998 4 6 378-384
31. 343915 Photodynamic therapy for corneal neovascularization. Prombs GB, Casey R, Wamser K, Snyder WJ, Crean DH Opthalmic Surgery Lasers 1998 29 10 832-838 This research paper showed that PDT with rostaporfin was a safe and effective means for producing extended occlusion of corneal neovascularization in a rat model.
32. 349096 Miravant exceeds enrollment goal in macular degeneration study. Miravant Medical Technologies Press Release 1999 November 30
33. 382638 Update on photodynamic therapy. Regillo CD Curr Opin Ophthalmol 2000 11 3 166-170 A review and update on photodynamic therapy.
34. 396630 Miravant announces non-binding letter of intent for additional funding & continuation of macular degeneration trials to two-year endpoint. Miravant Medical Technologies Press Release 2001 January 22
35. 411190 Miravant secures $20 million funding from Pharmacia - Pharmacia to purchase PhotoPoint drug SnET2 and expand line of credit. Miravant Medical Technologies Press Release 2001 May 30
36. 416360 A photobiological and photophysical-based study of phototoxicity of two chlorins. Pogue BW, Ortel B, Chen N, Redmond RW, Hasan T Cancer Res 2001 61 2 717-724
37. 434859 Verteporfin: A milestone in opthalmology and photodynamic therapy. Brown SB, Mellish KJ Exp Opin Pharmacother 2001 2 2 351-361 This is an ineresting account of the key scientific discoveries and clinical activities that contributed to the development of the PDT drug Visudyne for the treatment of AMD.
38. 434860 Photodynamic therapy: Shedding light on the biochemical pathways regulating porphyrin-mediated cell death. Granville DJ, McManus BM, Hunt DW Histol Histopathol 2001 16 1 309-317 This article is a comprehensive review of the intracellular biochemical events triggered by the activation of porphyrin photosensitizers that leads to the death of different cell types.
39. 434862 Distribution of a photosensitizer within ocular tissues and blood. Crean DH, Gebhardt BM, Falco V, Brennan P, Shaw T, Peyman GA, Primbs GB Invest Ophthalmol Vis Sci 1997 38 S140
40. 435577 Miravant announces results of phase III study of SnET2. Miravant Medical Technologies Press Release 2002 January 11
41. 436074 The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Kessel D, Luo Y, Deng Y, Chang CK Photochem Photobiol 1997 65 422-426
42. 436118 US - Major pharmaceuticals: Attractive relative valuation. Kulja KR Credit Suisse First Boston 2002 January 04
43. 436279 Investment Analysis: Pharmacia Corp. Klebanow ER Argus Res Co 2001 December 19
44. 439372 US Sec Form 10K; For the year ending December 31, 2000. Miravant Medical Technologies Form 10-K 2001 March 12
45. 439384 Drug development pipeline: Rostaporfin. Miravant Medical Technologies Company Communication 2002 January 24 Laurens Lichty, Manager, Corporate Communications at Miravant, conformed that: In August 1998, Miravant announced that the company would not pursue further studies for the treatment of CMBC in order to focus on age-related macular degeneration (AMD). Since that date, the only active development programs with Pharmacia Corp have been in the field of ophthalmology.